Zobrazeno 21 - 29
of 29
pro vyhledávání: '"David Flyer"'
Autor:
Gregory M. Glenn, Robin McKenzie, Christina P. Villar, Sarah A. Frech, A. Louis Bourgeois, Robert M. Lavker, David Flyer
Publikováno v:
Infection and Immunity. 75:2163-2170
Transcutaneous immunization allows safe delivery of native heat-labile enterotoxin (LT) from Escherichia coli via application of a simple patch. Physical disruption of the stratum corneum can improve the efficiency of delivery. In the current study,
Autor:
David Flyer, Matthew B. Frieman, Gale Smith, Haiyan Mu, Gregory M. Glenn, Michael J. Massare, Ye V. Liu, Justin K. Taylor, Christopher M. Coleman
Publikováno v:
Vaccine
Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a
Autor:
Eloi Kpamegan, Louis Fries, Denise Courbron, Yingyun Wu, Gale Smith, Ziping Wei, Ramadevi Raghunandan, Gregory M. Glenn, David Flyer, Ye Liu
Publikováno v:
Vaccine. 31(40)
The recent emergence of severe human illness caused by avian-origin influenza A(H7N9) viruses in China has precipitated a global effort to rapidly develop and test vaccine candidates. To date, non-A(H7N9) H7 subtype influenza vaccine candidates have
Autor:
Hanxin Lu, Bin Zhou, Gregory M. Glenn, Margret Nathan, Ye Liu, Sarathi Boddapati, Jingning Li, Yingyun Wu, Gale Smith, Michael J. Massare, Rama Raghunandan, David Flyer
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 11, p e50852 (2012)
PLoS ONE, Vol 7, Iss 11, p e50852 (2012)
Respiratory Syncytial Virus (RSV) is an important viral agent causing severe respiratory tract disease in infants and children as well as in the elderly and immunocompromised individuals. The lack of a safe and effective RSV vaccine represents a majo
Autor:
Vladimir G. Frolov, Robert Chancey Seid, David Flyer, Larry Ellingsworth, Christian Ruiz, Jee Loon Look, Jason Schafer
Publikováno v:
Vaccine. 30(29)
Transcutaneous immunization (TCI) has become an attractive alternate route of immunization due to increase understanding of the skin immune system and to recent technical innovations in skin patch delivery systems. Basic principles of TCI have been d
Autor:
Jose Flores Figueroa, Jaime Belkind-Gerson, David Flyer, Pablo C. Okhuysen, Sally A. Breisch, Raniya N. Kassem, Olga Torres, Francisco G. Martinez-Sandoval, Juan Hm Meléndez-Romero, Gregory M. Glenn, Kazem Kazempour, Bo H. Andersen, Robin McKenzie, Ana S. Hoffman, Jane Halpern, A. Louis Bourgeois, Zhi-Dong Jiang, Sarah A. Frech, Norma H. Guerrero, Christina P. Villar, Edwin J. Asturias, Herbert L. DuPont
Publikováno v:
Lancet (London, England). 371(9629)
Summary Background Enterotoxigenic Escherichia coli (ETEC) is a major cause of travellers' diarrhoea. We investigated the rate of diarrhoea attacks, safety, and feasibility of a vaccine containing heat-labile enterotoxin (LT) from ETEC delivered to t
Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch
Autor:
Larry Ellingsworth, Gregory M. Glenn, Jianmei Yu, David Flyer, David Frerichs, Sarah A. Frech, Robert C. Seid
Publikováno v:
Expert review of vaccines. 6(5)
The skin is an attractive target for vaccine delivery. Adjuvants and antigens delivered into the skin can result in potent immune responses and an unmatched safety profile. The heat-labile enterotoxin (LT) from Escherichia coli, which acts both as an
Autor:
Kazem Kazempour, David Flyer, A. Louis Bourgeois, Gregory M. Glenn, Sarah A. Frech, Robin McKenzie, Arlene Bloom
Publikováno v:
Vaccine. 25(18)
Background An enterotoxigenic Escherichia coli (ETEC) vaccine could reduce diarrhea among children in developing countries and travelers to these countries. The heat-labile toxin (LT) of ETEC is immunogenic but too toxic for oral or nasal vaccines. M
Autor:
Hanxin Lu, Rama Raghunandan, Mimi Guebre Xabier, David Flyer, Louis Fries, Bin Zhou, Gregory M. Glenn, Michael J. Massare, Gale Smith
Publikováno v:
Vaccine
Highlights • RSV F nanoparticle vaccine induced palivizumab competing antibodies (PCA). • PCA is in excess of serum protective levels than IM injected palivizumab. • Live virus infection induces little or no PCA. • Passively administered RSV
- [1]
- « Předchozí
- 1
- 2
- 3